Initiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19
• Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)
• Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”
• Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers
• Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting
• Preoperative/procedural screening and testing for COVID-19
• Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic
• Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy
• Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible
• Consideration of minimizing surveillance/staging imaging during and after treatments